Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -6 of 6
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
10/1/1994
1.
Phase II Study of Continuous-Infusion DOX/VCR/VP-16 with Daily Oral Mitotane for Renal Cell Cancer (Summary Last Modified 10/94)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
NCI-94-C-0156
2.
Phase II Mitotane plus Cortisone Acetate/Fludrocortisone and ADR for Residual, Recurrent, or Metastatic Adrenal Cortical Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 to 75
NCI
EST-1879
Last Modified:
7/1/1989
3.
Phase II Chemotherapy with Mitotane/CACP for Metastatic or Residual Unresectable Adrenal Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
SWOG-8325
SEG-INT-GU-217
Last Modified:
9/1/1995
4.
Phase II Study of CDDP/VP-16 Alone or Followed at Progression by Mitotane (If No Prior Mitotane Therapy) in Patients with Unresectable Adrenocortical Carcinoma (Summary Last Modified 09/95)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
13 and over
NCI
SWOG-8925
Last Modified:
10/1/2002
5.
Phase II Study of Continuous-Infusion DOX/VCR/VP-16 with Daily Oral Mitotane Before and After Surgery in Patients with Adrenocortical Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
NCI
NCI-93-C-0200D
NCI-93-C-0200B
Last Modified:
9/25/2008
 
First Published:
11/20/2003
6.
Phase II Study of Combination Chemotherapy Comprising Tariquidar, Mitotane, Doxorubicin, Vincristine, and Etoposide and Surgery in Patients With Recurrent, Metastatic, or Primary Unresectable Adrenocortical Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
NCI-04-C-0011
NCT00073996
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute